SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The market is focused on the expected interest rate decision, with community chatter split between anticipating a rally or a "sell the news" reaction. Many traders believe a 0.25% rate cut is already priced in, while others are closely watching Fed Chair Powell's commentary for further cues on the economic outlook and future monetary policy. Community members also discuss potential sector rotations and the impact of rate decisions on various asset classes.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market anticipates the Fed's rate decision, with widespread expectation of a 25 bps cut. Community members are closely watching Powell's tone and forward guidance, as well as potential sector rotations and the impact on small caps. Uncertainty surrounding inflation and labor market conditions adds to the speculation around the technology-heavy index.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor (OPEN) is trending amid discussions about the Federal Reserve's rate cut decision and its potential impact on the housing market; the community is debating whether the rate cut will stimulate growth or if it was already priced in. Some traders are pointing to the company's expansion plans as a catalyst, while others speculate about potential announcements from the CEO. Overall, the conversation revolves around the tug-of-war between bullish hopes for real estate and bearish concerns about market reactions.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as investors anticipate the Fed's rate cut decision and its potential impact on crypto markets, with some expecting a bullish outcome and others bracing for a "sell the news" event. Community members are actively discussing potential price targets, the influence of rate cuts, and the performance of altcoins relative to Bitcoin. Broader discussions encompass Bitcoin's role as a store of value and its correlation with traditional markets.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending due to anticipation surrounding a potential Federal Reserve rate cut, with the market pricing in possible easing. Community discussions revolve around the impact of rate cuts on small-cap stocks and whether the expected news is already priced in, potentially leading to a "sell the news" event. Traders are closely watching for signals about the Fed's future policy and its effects on various sectors, especially small caps.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending due to a combination of factors, including increased institutional buying from Goldman Sachs and a congresswoman's disclosed investment. The community is actively discussing the potential for a short squeeze and the impact of upcoming Fed decisions on the stock's momentum, as well as potential government contracts. Overall sentiment appears bullish, with many anticipating further gains and a breakout above key resistance levels.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders anticipate potential Fed rate cuts following recent economic data and await upcoming CPI and PPI reports, leading to discussions about recession risks and the bond market's next move. Community perspectives range from expectations of a bond rally to concerns about stagflation, with some highlighting the influence of tariffs and potential central bank actions. The conversation also involves analysis of technical indicators and potential trading strategies.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending due to speculation around potential Fed rate cuts following weaker-than-expected jobs data, with the community debating whether this is a bull trap or a genuine signal for further market gains. Community members are closely watching upcoming inflation reports for further clues, while some express concern about the reliability of economic data. Debate continues about whether to "buy the dip" or prepare for a significant correction.

TOSHI

TOSHI.X is trending amid community excitement around new exchange listings, particularly in South Korea, and speculation about potential future listings on major platforms like Binance. Talk of a recent partnership with Coinbase is circulating, as well as anticipation surrounding potential interest rate cuts and their impact on the crypto market. The community is also actively discussing the coin's technical outlook and potential for significant gains.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Conversations around Webull Corp (BULL) are focused on potential dilution and reverse splits, with some traders expressing frustration over the stock's performance despite broader market gains and upcoming rate cut decisions. Community sentiment is mixed, with some calling it a "garbage" stock and others anticipating a potential short squeeze or a move to higher price targets, especially with the potential of rate cuts. Some are drawing comparisons to similar companies, mentioning potential catalysts to be a breakout stock like competitors $HOOD and $SOFI.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Should You Invest in the VanEck Biotech ETF (BBH)?

ASL Strategic Value Fund is calling for shareholders of Avadel Pharmaceuticals to vote out the company’s entire board of directors.According to a letter viewed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/avadel-shareholder-seeks-ousting-drugmakers-entire-board-fa071ead">The Wall Street Journal</a>, ASL alleges that Avadel mishandled the launch of its key drug, Lumryz, resulting in the company missing out on hundreds of millions of dollars in potential revenue.&nbsp;The investment firm reportedly plans to vote its $15 million stake against all of Avadel’s director nominees at the company’s annual meeting scheduled for late July.The company has been involved in litigation with its main competitor in narcolepsy, Jazz Pharmaceuticals, over patent disputes.In the letter, ASL called on Avadel to issue contingent-value rights (CVRs) to shareholders, which are future payouts tied to possible legal settlements or damages.&nbsp;One of Avadel’s ongoing cases seeks damages in excess of $1 billion.ASL further reiterates its previous demand, first made in February, that Avadel hire an investment bank to explore strategic alternatives, including a potential sale of the company.In response, a spokesperson for Avadel said the board proactively engages with shareholders and that its directors have made personal investments in the company.&nbsp;The company spokesperson further noted that the company continues to focus on “unlocking the full value of Lumryz.”In May, Avadel reported better-than-expected first-quarter sales and raised full-year revenue guidance due to improving demand for Lumryz.The pressure on Avadel comes amid weak performance across the biopharma sector.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The SPDR S&amp;P Biotech ETF</a> is down 9.3% over the past year, while the&nbsp;<a href="https://stocktwits.com/symbol/SPX">S&amp;P 500</a> has gained 5.2%.<a href="https://stocktwits.com/symbol/AVDL">Avadel</a> is a $900 million market cap stock that has seen its&nbsp;stock price rise by 16.4% over the past year.&nbsp;On Stocktwits, retail sentiment for Avadel was ‘neutral’ amid ‘low’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One of Avadel’s ongoing cases seeks damages in excess of $1 billion. Representative image via Getty Images

Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according to a WSJ report.

Equity

Capricor Therapeutics (CAPR) said on Tuesday that the U.S. Food and Drug Administration is not eyeing an advisory committee meeting regarding approval for its Deramiocel for the treatment of Duchenne Muscular Dystrophy (DMD) associated cardiomyopathy.Capricor shares were trading 19% higher at the time of writing.The FDA indicated that an advisory committee meeting is not required at this time, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/318/capricor-therapeutics-provides-regulatory-update-on">said</a>, while adding that its application for Deramiocel approval remains under priority review.The company said in May that the FDA is considering an advisory committee meeting, dragging down investor optimism for a possible approval.The agency is expected to decide on the approval of the drug by Aug. 31. &nbsp;Company CEO Linda Marbán said that all regulatory milestones to date have proceeded as expected, and no major issues were noted at the mid-cycle review of the application.An in-person late-cycle meeting is now scheduled for mid-July.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_58_45_PM_png_3f23c3492d.webp" alt="CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the drug getting approved early following the company’s update.<stembedurl>https://stocktwits.com/Drichman7/message/618833665</stembedurl>However, Roth Capital analyst Boobalan Pachaiyappan told investors in a research note that the FDA's intention not to require a meeting "at this time" for Deramiocel “may not necessarily be positive news.”The analyst believes a promissory advisory committee meeting would be positive, as a potential positive panel vote would put pressure on the new FDA leadership to approve deramiocel in its current form.The firm reiterates a ‘Buy’ rating and $31 price target on Capricor shares.H.C. Wainright, however, opined that even in bear case scenarios with the FDA, late-stage trial data readouts are "waiting in the wings" to further strengthen Deramiocel's overall clinical and regulatory package. The analyst believes Deramiocel's first-in-class therapeutic profile, in tandem with strong manufacturing support, will get the therapy over the finish line on expected timelines, as per TheFly.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 34% this year but up by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-presses-congress-to-pass-tax-bill-and-get-the-deal-done-this-week-after-iran-israel-ceasefire/chm4iPpRR3L">Trump Presses Congress To Pass Tax Bill And ‘Get The Deal Done’ This Week After Iran-Israel Ceasefire</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy have been placed on administrative leave.Stat News on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/06/18/top-gene-therapy-regulator-forced-out-at-fda/">reported</a>, citing a recording of a meeting, that Verdun and her deputy Rachael Anatol were escorted out of the agency, sending CAPR shares down on Friday morning. Verdun was the FDA's key overseer of Capricor's application for approval of its Deramiocel drug.Capricor on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/317/capricor-therapeutics-announces-positive-4-year-data-from">announced</a> positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Last month, Capricor announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is now planned for mid-July.Capricor on Friday said that after four years of continuous treatment, Deramiocel-treated patients showed preservation of cardiac function, including Left Ventricular Ejection Fraction, which is a measurement of how well the left ventricle, the heart's main pumping chamber, is working.Treatment also continued to slow the progression of skeletal muscle disease, the company said, while adding that the findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time.CEO Linda Marbán said that the company is moving toward potential approval of the therapy, with several key regulatory steps now completed.“Our continued dialogue with the FDA remains on track with no evidence of any delays,” she said.On Stocktwits, retail sentiment around Capricor jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_10_35_01_AM_png_6034c09f71.webp" alt="CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that, although things don't look good, the new 4-year data from the study could ‘change things’ for Capricor.<stembedurl>https://stocktwits.com/MrMarB/message/618459744</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by 33% this year but has more than doubled its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/uniswap-uni-fair-gas/chlxZJTRRPA">Uniswap Makes Fees Someone Else’s Problem</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Shares of Capricor Therapeutics (CAPR) were in the spotlight on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/11/3097631/0/en/Capricor-Therapeutics-Announces-Key-Regulatory-Updates-for-its-Duchenne-Muscular-Dystrophy-Program.html">announced</a> the completion of the U.S. Food and Drug Administration’s (FDA) Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel.Deramiocel is the company’s lead cell therapy candidate. It is under FDA review for potential approval in the treatment of Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles.No material changes are required to the manufacturing process or the facility following the inspection, the company said.While the FDA made observations, they were primarily related to routine quality systems and documentation practices, it added.Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.Capricor is now looking to present evidence in support of an approval for Deramiocel in an upcoming advisory committee meeting. While the FDA has expressed intent to hold the meeting on July 30, it is yet to be confirmed by the agency, Capricor said.Last month, the company announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is also planned for mid-July.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘bullish’ territory over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_11_38_14_AM_png_cc62744706.webp" alt="CAPR's Sentiment Meter and Message Volume as of 11:38 a.m. ET on Jun 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CAPR's Sentiment Meter and Message Volume as of 11:38 a.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Deramiocel, opining that the technology has “unimaginable potential.”<stembedurl>https://stocktwits.com/snowboy/message/617558955</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 10% this year but up by about 143% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-inks-812-million-deal-wth-deep-apple-therapeutics/chlaHHKRbCH">Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’

Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.

SPDR Series Trust - SPDR Biotech ETF

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XBI News

XBI SPDR S&P Biotech ETF